Introduction
In June 2009, the WHO declared the first influenza pandemic of the 21st century. 1 To combat this, pandemic vaccines have been developed and first became commercially available in September 2009. Data on the effectiveness of these vaccines are very limited; however, several studies have evaluated immunogenicity (especially seroprotection) and safety of the vaccine.
The immunogenicity and safety of various formulations of novel H1N1 vaccine have been assessed in various populations and age groups comparing different dosages (1AE875-30 lg antigen per dose; single or two doses) with or without adjuvants (e.g. AS03 A , AS03 B , MF59, alum). Now that over a dozen trials have been reported, there is scope for a meaningful systemic review and meta-analysis to assess the immunogenicity (in particular, seroprotection) and safety of the 2009 influenza A (H1N1) vaccine formulations. This will inform decision-making about the most appropriate dose and formulation of pandemic vaccines. Given possible restrictions on antigen availability, the best compromise between the lowest possible dose and protective immunity is an important consideration.
Methods

Literature search and selection criteria
We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and other clinical trial registries (ClinicalTrial.gov, WHO, and international We included clinical trials measuring serological response to, or adverse events from, pandemic (H1N1) 2009 vaccine at different doses, with or without adjuvant and with or without a control arm, given to healthy people from different age groups.
Outcome measurement
Immunogenicity
We assessed the immunogenicity of pandemic (H1N1) 2009 vaccine using seroprotection (proportion of individuals with post-vaccination HI titre ‡1:40) measured by HI assay. Regulatory agencies require at least 70% of the population aged <65 years to achieve this for a vaccine to be approved. [2] [3] [4] The existence of a strong relationship between the HI titre and clinical protection against influenza is recognised, so we assumed that HI titre can be used as a proxy for the protection of inactivated influenza vaccines before vaccine effectiveness data become available from clinical studies. 5, 6 We reported the pre-vaccination antibody level for each age group. We do not report microneutralisation data here; few studies [7] [8] [9] included it and the results do not materially affect our conclusions. We also compared the seroprotection of non-adjuvanted with adjuvanted vaccines (specifically by comparing vaccines produced by the same company) and expressed the results as risk ratios for the proportion achieving seroprotection in those given non-adjuvanted versus adjuvanted vaccine; this means that a risk ratio significantly >1 indicates that the non-adjuvanted vaccine is superior.
Adverse events
The common adverse events of influenza vaccination can be classified into systemic events, including fever, headache, muscle aches, malaise and local events (injection site), which may include pain, redness and tenderness.
As different studies may use different definitions for adverse events, we adopted easy to understand or commonly used definitions. We also looked for serious adverse events, such as death, hospitalisation, Guillain-Barre syndrome, disability and life-threatening events.
Validity assessment and data extraction
For each study, data extraction and validity assessment were performed by two reviewers (authors: JY, GK) independently. Data extracted included study design, study location, age group of participants, vaccine type, whether adjuvants were used or not, types of adjuvant, dose administered, immunogenicity and adverse events. Any disagreement was solved by discussion or by consulting with the review supervisor (RB). We used the Jadad scoring system to examine the methodology (randomisation, blinding and withdrawals). 10 
Statistical analysis
We used Meta-Analyst 3AE13 (Tufts Medical Centre) for meta-analysis. 11 For the point estimate of immunogenicity and 95% confidence intervals (CI), we chose binary analysis with Random (D ⁄ L) as the model type and Der-Simonian Laird as the random method. We also used risk ratios to compare the immunogenicity of related (same company) adjuvanted and non-adjuvanted vaccines. Heterogeneity between studies, defined as variation among the results of individual studies beyond that expected from chance, was tested with I 2 statistic for each overall estimate using the same software. Heterogeneity is considered to be mild if I 2 < 30% and moderate when I 2 = 30-50%; while notable heterogeneity may account for >50% of the variability in point estimates. 12, 13 We did heterogeneity tests for each overall estimate of forest plot, which include (i) pre-vaccination antibody level, (ii) seroprotection after 1st and 2nd dose of non-adjuvanted and (alum ⁄ AS03 A ⁄ AS03 B ) adjuvanted vaccine and (iii) risk ratio of head-to-head comparison (non-adjuvanted versus aluminium hydroxideadjuvanted vaccine at the same dose). Each overall estimate generated from forest plot was reported in a format of 'weighted estimated, 95% CI, I
2 , P value of heterogeneity test'.
Results
Of the 322 papers initially retrieved ( Figure S1 ), 16 studies 7-9,14-26 assessed both immunogenicity and safety, while one other 27 was a review of safety reports from Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD), and another study 28 just reported immune response without safety data. We contacted the authors and found that all the data from one Chinese trial 26 published in NEJM were also reported as part of another larger Chinese study 17 published in The Lancet. Therefore, we included the data only once in our analysis.
A total of 17 921 subjects were involved. Fourteen of 17 studies included (Table S1 ) were randomised trials. Four studies used placebo as a control. 17, 21, 25, 26 One study compared pandemic vaccine with pandemic and seasonal influenza vaccine receipt, so we extracted data only from the arm using pandemic vaccine 24 ; no others had a control vaccine. One trial 7 only used seed virus grown in cell culture, 15 used egg-based vaccines and the other one 9 used both. They all determined immune responses 21 days after the first and ⁄ or second doses, respectively. Seven of these 17 studies examined both adjuvanted and non-adjuvanted vaccines, three assessed only an adjuvanted vaccine and the other seven evaluated only non-adjuvanted vaccines. 19, 21 Three studies each were from mainland China and Taiwan, and two studies each were from Australia and the UK, with one each from the USA, Hungary, Costa Rica, Republic of Korea, Spain, Belgium and Germany. Details of study design and methodological quality are in Table S1 . Serological responses were most commonly described as the proportion of participants with antibody titres ‡1:40 measured by haemagglutination inhibition (HI) assay (i.e. seroprotection). One study 9 used 1:32 and we included it as if 1:40 in our analysis. Sixteen studies [7] [8] [9] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] 25, 26, 28 reported pre-vaccination antibody level, and baseline forest plots are given in Figure S2 .
All the studies included in this review were clinical trials and published in peer review journals with high impact factors. We have calculated the JADAD score for individual studies and all were three or higher, except for two studies 14, 18 (Table S1 ).
Immunogenicity
Children aged 6-35 months Five studies 15, [18] [19] [20] [21] provided pre-vaccination serological data on 1001 children; the percentage with antibody ‡1:40 was 5AE8% (95% CI: 4AE0-8AE4%, I 2 = 30AE9%; Figure S2 ). Nine hundred and sixty-seven children were vaccinated and followed; 135, 170 and 131 of them, respectively received a 7AE5, 15 or 30 lg dose of non-adjuvanted vaccine. A total of 324 children received oil in water emulsion vaccines (48, 175 and 101 children, respectively were given 3AE75 lg AS03 A -, 1AE875 lg AS03 B -and 1AE9 lg AS03 B -adjuvanted vaccine).
After 1st ⁄ one dose of non-adjuvanted vaccine, the overall weighted proportion with a HI titre ‡1:40 was 56AE9% (33AE0-78AE0%, I 2 = 48AE0%); those who were given two doses of non-adjuvanted vaccine had higher seroprotection, 83AE6% (64AE9-93AE4%, I 2 = 46AE1%; Table S2 and Figure S3 ). Participants receiving AS03 A or AS03 B vaccine achieved a proportion of 99AE3% (95AE2-99AE9%, I 2 = 0AE000) after one dose and 99AE4% (97AE5-99AE8%, I 2 = 0AE000) after two doses of AS03 A or AS03 B vaccine. The poorest responses were to non-adjuvanted vaccine produced by local manufactures in Republic of Korea and Taiwan. 18, 20 As the study by Oh 20 had low Jadad score, we performed a sensitivity analysis without it; higher seroprotection proportions were shown, 67AE7% (44AE3-84AE7%, I 2 = 48AE0%) after 1st dose of non-adjuvanted vaccine and 91AE5% (71AE2-97AE9%, I 2 = 46AE8%) after the 2nd dose.
Children aged 3-8 years There were five reports 14, [18] [19] [20] [21] and these included preand post-vaccination data, respectively from 751 and 746 children. The pre-vaccination proportion was 14AE0% (8AE1-23AE2%, I 2 = 46AE6%; Figure S2 ). Both the Arguedas 14 and Nolan 19 studies reported high antibody percentage before vaccination (up to 33AE3% seroprotected). The overall estimate for seroprotection after 1st ⁄ one dose of non-adjuvanted vaccine in this age group was 74AE8% (60AE0-85AE4%, I 2 = 48AE0%; Table S2 and Figure S3 ) with poorer responses (as before) after the locally produced vaccines from Republic of Korea and Taiwan. 18, 20 The Nolan study (nonadjuvanted product) stood out for showing the highest immune response to vaccination. The adjuvanted vaccine (with MF59) had 7AE5 lg haemagglutinin (HA) and induced a higher antibody level (seroprotection = 92AE6%, 81AE9-97AE2%), compared with the non-adjuvanted vaccines containing 15 and 30 lg, although it was only significantly so with the 15 lg of vaccine. Among children receiving two doses, there was even higher seroprotection (Table S2 and Figure S3 ).
As there was limited information on methodological quality in two reports, 14, 20 we performed a sensitivity analysis without them; the overall estimate of seroprotection after one dose (non-adjuvanted vaccine) was actually higher at 81AE2% (64AE7-91AE1%, I 2 = 47AE8%). After the 2nd dose, the separate analysis without the data from Oh only was also higher, 97AE9% (76AE6-99AE9%, I 2 = 44AE4%).
Adolescents aged 9-17 years
Four studies 14, 17, 18, 20 provided data about pre-vaccination seroprotection in 3120 subjects: 19AE3% (8AE3-38AE8%, I 2 = 49AE1%; Figure S2 ) and post-injection seroprotection data from 3036 subjects, 2684 of whom came from a Chinese trial. 17 The summary-weighted estimate for those receiving non-adjuvanted vaccine was higher at 95AE7% (90AE9-98AE0%, I 2 = 47AE5%) after the 1st ⁄ one dose than after aluminium hydroxide-adjuvanted vaccine (1st dose: 88AE1%, 80AE2-93AE2%, I 2 = 42AE7%; Table S2 and Figure S3 ). MF59-adjuvanted split vaccine was administrated to 52 subjects and produced a better immune response (98AE1%, 87AE6-99AE7%) than other adjuvanted (aluminium hydroxide) and nonadjuvanted vaccines (Table S2 and Figure S3 ). The analysis without data from Arguedas or Oh showed the overall estimate after one dose of non-adjuvanted vaccine was not materially affected [96AE8% (95AE2-97AE9%, I 2 = 35AE8%)]. Two doses of non-adjuvanted vaccine lead to a proportion with seroprotection rate of 99AE3% (93AE5-99AE9%, I 2 = 46AE8%), which was again higher than the immune response to aluminium hydroxide-adjuvanted vaccine (95AE2%, 90AE6-97AE8%, I 2 = 32AE1%). The sensitivity analysis without the study by Oh gave a slightly higher proportion after 2nd dose of non-adjuvanted vaccine, 99AE7% (98AE0-99AE9%, I 2 = 37AE6%).
Adults aged 18-60 years Eight trials had data on seroprotection proportion estimate of 4458 participants 7, 8, 16, 17, [22] [23] [24] [25] and reported an estimate of 10AE2% (6AE0-16AE8%, I 2 = 48AE1%; in two studies, there were higher proportions 7, 8 ; Figure S2 ). Seroprotection data showed overall estimates of 92AE9% (89AE0-95AE5%, I 2 = 45AE5%; Table S2 and Figure S3 ) after 1st ⁄ one dose of non-adjuvanted vaccine, 82AE1% (76AE7-86AE5%, I 2 = 42AE8%) after alum-adjuvanted vaccine and 93AE8% (79AE1-98AE4%, I 2 = 43AE8%) after MF59-or AS03 A -adjuvanted vaccine. Further improvements were detected for all vaccine types after 2nd dose (non-adjuvanted: 95AE9%, 92AE5-97AE8%, I 2 = 44AE8%; alum-adjuvanted: 90AE7%, 83AE9-94AE8%, I 2 = 45AE6% and MF59 ⁄ AS03 A : 97AE8%, 91AE7-99AE5%, I 2 = 0AE000).
The elderly (aged >60 years)
The pre-injection seroprotection proportion was estimated as 9AE6% (4AE3-20AE1%, I 2 = 48AE8%) based on the data of 2778 subjects ( Figure S2 ). The seroresponse results were obtained for 2692 participants from six trials. 16, 17, 21, 23, 24, 28 After 1st ⁄ one dose of non-adjuvanted vaccine, the overall seroprotection estimate was 87AE3% (82AE3-91AE0%, I 2 = 45AE4%; Table S2 and Figure S3 ); a lower response was shown in those that received aluminium hydroxide-adjuvanted vaccine, 68AE1% (57AE6-77AE0%, I 2 = 43AE6%). With a low antigen dose (3AE75 lg) of AS03 A -adjuvanted vaccine, a high proportion, 87AE4% (80AE1-92AE3%), achieved seroprotection. After 2nd dose, all types of vaccine reported better immune responses (non-adjuvanted: 91AE2%, 79AE7-96AE5%, I 2 = 48AE4%; aluminium hydroxide-adjuvanted: 91AE5%, 85AE5-95AE1%, I 2 = 33AE4%; AS03 A -adjuvanted: 97AE0%, 88AE8-99AE3%).
Comparisons of adjuvanted vaccines versus non-adjuvanted vaccines produced by the same company
Based on the data from two studies 17, 25 (one study 17 had a third one 26 as a subset), use of aluminium hydroxide as an adjuvant did not improve the immune response compared with non-adjuvanted vaccine, and in fact, it was significantly decreased after one dose in three age groups, 9-17, 18-60 and >60 years compared to a plain split vaccine ( Figure S4 ). One study 7 showed a higher seroprotection proportion in participants vaccinated with MF59-adjuvanted vaccine (77-96% after 1st dose and 92-100% after 2nd dose) than those who were given nonadjuvanted vaccine (63-72% after 1st dose and 67-76% after 2nd dose). of which also collected unsolicited adverse events. One study 14 did not report the collection method of adverse events. The common local and systematic adverse events were defined and collected in each study; however, some studies reported adverse events by combining vaccine doses, with ⁄ without adjuvants and age groups, and also different grading scales are observed among these studies. Therefore, we are not able to synthesise these data by meta-analysis.
Adverse events
The pandemic influenza A (H1N1) vaccines were associated with two serious adverse events: one 8-year-old child developed an episode of 4-day high fever (39AE7°C) within 1 day of the first vaccination (no adjuvant, 30 lg).
19 This child made a full recovery. One adult with multiple allergies and mastocytosis had allergic symptoms 1 hour after receiving the first dose of non-adjuvanted (30 lg HA) vaccine and this event also revolved. 22 No death or case of Guillain-Barré syndrome (GBS) was reported. The severities of local and systematic adverse events were relatively mild to moderate, although high proportions of some adverse events were reported (pain: 88AE9%; muscle aches: 54AE0%; Table S3 ). Pain at the injection site after vaccination was the most frequently reported local adverse event in 14 of the 16 studies, followed by swelling and redness. Fever and headache were reported to be the most common systematic adverse events with malaise and muscle aches also quite common. A proportion of 10AE9% (4AE9-16AE1%) of children under 3 years developed fever (>37AE5°C) after the vaccination (Table S5 ). There was one febrile convulsion reported among 967 children aged 6 months to 3 years and none in 746 aged 3-8 years; it was stated to be associated with concurrent pneumonia. 19 Mild systematic adverse events (nausea, vomiting, diarrhoea, fever and irritability) were frequently found among children aged 6-35 months; the proportions of fever (>37AE5°C) were 10AE9% and 4AE4%, respectively, in children aged 6-35 months and 3-8 years (Tables S4 and S5 ).
There were only three studies 7, 17, 25 where comparisons were made between adjuvanted and non-adjuvanted vaccines at the same dosage. Two Chinese studies 17, 25 involving 13 397 participants given influenza vaccine with or without aluminium hydroxide adjuvant showed in general that local and systemic reactions were more common with the alum-adjuvanted product. In the large study (in The Lancet) by Liang et al.,
17 aluminium hydroxide-adjuvanted vaccine was associated with a significantly higher proportion of local reactions; however, the smaller study by Wu et al. 25 did not report any significant differences; the third study 7 involving 176 adults compared recipients of an MF59-adjuvanted vaccine with those given non-adjuvanted vaccine. Pain was the most frequent local reaction and was more common with MF59-adjuvanted vaccine (65% versus 39%, P = 0AE003). Participants receiving two doses of MF59-adjuvanted vaccine had a higher proportion of muscle ache (P = 0AE02) than those who were given one dose only, whereas no significant difference of systemic reactions, in frequency or severity, was detected between MF59-adjuvanted and non-adjuvanted vaccines.
The CDC review of safety data on non-adjuvanted vaccines 27 looked at nearly four thousand reports from the US VAERS and examined more than 430 000 electronic records in VSD. There was no significant difference detected between pandemic H1N1 and seasonal influenza vaccines in terms of serious adverse events, although they found somewhat more adverse events post-vaccination with H1N1 vaccine compared with seasonal influenza vaccine (82 versus 47 reports per 1 million vaccine doses distributed). During December 2009-August 2010, the European Medicines Agency provided regular updates of safety surveillance data on both non-adjuvanted and adjuvanted vaccines. It concluded that the benefit-risk profile of pandemic H1N1 vaccine, with or without adjuvant, continued to be positive, and the majority of post-vaccination adverse events were considered to be non-severe. 29 
Discussion
Pandemic influenza A (H1N1) 2009 vaccine, with or without adjuvant, at most doses, was immunogenic and generally safe in people aged from 36 months to over 60 years. A striking finding is that both healthy young children (in 2 of 5 studies) and the elderly (in 7 of 7 studies) could respond vigorously to just one dose of vaccine and fulfilled the seroprotection criteria of leading regulatory agencies. 2, 3 As the existence of a strong relationship between HI titre and clinical effectiveness against influenza has been confirmed recently, 5 we are able to provide timely information for governments, academics and medical practitioners on the new pandemic vaccines; this is not contingent on comparing the data with past meta-analyses of seasonal vaccines. 30, 31 The three studies 18, 20, 21 in young children (6-35 month) where immunogenicity did not fulfil seroprotection criteria all involved non-adjuvanted vaccine. Two 18, 20 of these studies were by manufacturers where vaccines proved generally less immunogenic in all paediatric age bands. One study showed one dose of 15 lg non-adjuvanted vaccine was highly immunogenic 19 comparing favourably with the 70% cut-off. The apparent better immune response to vaccine among young children (6-35 months) in the Nolan (Australian) study 19 and the poorer responses in other studies 18, 20, 21 need to be interpreted in the context of assays not all being performed by the one laboratory. The higher pre-vaccination antibody titres in Australian children may indicate some were primed by mild ⁄ asymptomatic infections with H1N1 2009 virus; it is noteworthy that date of recruitment in Australia was no later than the other studies (in Republic of Korea, 20 Taiwan 18 and United States 21 ), but the Australian study was performed in August in the Southern Hemisphere winter when the disease was peaking ( Figure S2 ). Use of single-dose AS03 A -or AS03 B -adjuvanted vaccine lead to generally higher immunogenicity despite a low amount of antigen; a 2nd dose of non-adjuvanted vaccine is likely to be required in this age group as only one of four studies showed a strong response to one dose. 19 Two doses were recommended by authorities for young children. 27, 32 Even after two doses, there were two studies using non-adjuvanted vaccine at the 7AE5 lg dose that did not demonstrate adequate immunogenicity, 9, 20 whereas six other comparisons 9, 15, 18, 19 using 15 or 30 lg non-adjuvanted, or lower dose (1AE9 or 3AE75 lg) AS03 A ⁄ AS03 Badjuvanted vaccines, resulted in adequate levels of antibody response.
Single-dose vaccine performed well in adults aged 18-60 years ( Figure S3 ). It was clear in this age group that there were better responses to the adjuvanted (MF59 or AS03 A ) vaccines, despite lower antigen contents. Based on the consideration that, in order to cover large numbers, the lowest dose vaccine may be needed during a pandemic, use of MF59-or AS03 A -adjuvanted vaccine would contribute to an increase in vaccine production.
Use of aluminium derivatives as adjuvants did not improve the immune response. Indeed, results were significantly worse compared to a non-adjuvanted split virus vaccine. Notable heterogeneities were detected among five of six overall estimates. These findings were drawn from two studies, 17, 25 both of which used batches of vaccines provided by the same pharmaceutical company in China, so caution is required before discounting the value of aluminium hydroxide or alum adjuvants altogether. However, research with H5N1 vaccines has also shown no benefit (and perhaps detriment) from using alum adjuvants. 33 Meta-analysis of safety outcomes is particularly difficult, because, in the main, of poor uniformity in documenting outcomes. Also, there were only three studies e.g. that compared, head-to-head, adjuvanted vaccine against non-adjuvanted vaccines. There was a suggestion that alum-adjuvanted vaccine was less well tolerated. There was some statistical evidence that pain after injection and muscle ache were more frequent with a MF59-adjuvanted vaccine compared with non-adjuvanted vaccine. In 1976, the vaccine for a swine-origin influenza virus was shown to have significant association with higher risk of GBS among the vaccinated population, the reason for which remains unknown. The trials in this review included healthy volunteers only and had relatively small size; therefore, although no cases of GBS were reported, surveillance systems at the general population level are required to better assess the safety profile of pandemic H1N1 vaccine in term of rare adverse events.
In Western Australia (WA), there were reports of increased febrile convulsions after 2010 seasonal influenza vaccination that included pandemic H1N1 strain. However, a definitive explanation has not yet been found. 34 Among the children aged <3 years that received monovalent pandemic H1N1 vaccine, there was just one episode of febrile convulsion reported (an 18-month-old boy, 20 days after 1st dose of 15 lg non-adjuvanted vaccine) 19 and was considered to be non-vaccine associated by the authors.
Mild to 'notable' heterogeneities are detected in most of the overall estimates (28 of 31 estimates, I
2 : 30AE9-91AE0%). As not all studies provided detailed information, we are not able to perform full analysis for the sources of heterogeneity. However, we believe that the heterogeneities may be associated with: (i) substantially higher pre-vaccination antibody level in some groups of vaccinees. Participants in studies by Plennevaux 21 This study has some other limitations. Our review included several studies of lower quality (Jadad scores of 1 in 2 studies 14,18 and 3 in 7 studies 7, 9, 14, 15, 18, 20, [23] [24] [25] ). However, sensitivity analyses removing the two lowest quality studies made no material difference to the estimates. The measurement of immunogenicity has some limitations. First, immunogenicity in our meta-analysis only refers to the antibody against the homologous virus contained in the monovalent vaccine (A ⁄ California ⁄ 07 ⁄ 2009-A ⁄ PR ⁄ 8 ⁄ 34); however, this virus has been reported to have developed some phylogenetic clades and different subclades. 35 Secondly, the degree of association between immunogenicity and clinical efficacy needs to be further evaluated despite recent supportive evidence. 5 Thirdly, there is known to be considerable inter-laboratory variation in antibody measurement and an antibody standard was not routinely applied. Finally, we did not report data on seroconversion or on microneutralisation titres as these were not routinely available.
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